Patient-derived organoids reveal which breast tumors may resist standard therapies
Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors.
Researchers at the University of California, San Francisco have created a method to predict how breast cancer patients may respond to treatment using organoids, which are lab-grown mini tumors derived from patients. These organoids can mimic how a patient's actual tumor will react to various therapies. The study, published in Cell Reports Medicine, found that the organoids could identify which cancers may resist standard treatments, particularly triple-negative breast cancer, which is aggressive and hard to treat.
The researchers used patient data from the I-SPY2 breast cancer trial and tested these organoids under different treatments, discovering drug combinations that showed promise in overcoming resistance to standard therapies like veliparib-platinum chemotherapy. While the organoids cannot fully replicate the complexity of a real tumor, the study highlights the potential of this approach to develop personalized cancer treatments in the future.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
